Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$53.30

-0.1401 (-0.26%)

14:07
04/21/17
04/21
14:07
04/21/17
14:07

Bristol-Myers receives 'positive' CHMP opinion on Opdivo approval

Bristol-Myers Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. Opdivo is the first and only PD-1 immune checkpoint inhibitor for the treatment of patients with previously treated mUC to receive a positive CHMP opinion. Opdivo is already approved by the EC for six indications in four distinct tumor types. "We view the CHMP recommendation of Opdivo for previously treated locally advanced or metastatic urothelial carcinoma as an important milestone for the patients. Bristol-Myers Squibb looks forward to collaborating with the European Commission as it considers this potential new indication for Opdivo," said Murdo Gordon, executive vice president and chief commercial officer, Bristol-Myers Squibb.

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 06

    Jun

BMY Bristol-Myers
$53.30

-0.1401 (-0.26%)

03/08/17
PIPR
03/08/17
NO CHANGE
Target $60
PIPR
Neutral
Piper views near-term takeout of Bristol-Myers as unlikely
In a research note titled "Lung Data to Define Value....Not M&A Talk," Piper Jaffray analyst Richard Purkiss contends that news reports suggesting Bristol-Myers (BMY) is a takeover target are "wide of the mark." Industry buyers are unlikely to show interest ahead of the immuno-oncology data readouts in the next 12 months, Purkiss tells investors. He believes the key value-defining events for Bristol over the next year are the four large I/O Combo studies set to read out from mid-2017: AstraZeneca's (AZN) MYSTIC, Merck's (MRK) KN-189, Roche's (RHHBY) IMpower 150 and the company's own CheckMate-227. Ahead of these data, it is virtually impossible to assign a stable fair value to Bristol's I/O franchise, Purkiss argues. He believes investors seeking to benefit from industry consolidation in the near-term should own small- or mid-cap oncology companies. The analyst has a Neutral rating on Bristol with a $60 price target. The stock closed yesterday down 64c to $56.33.
04/03/17
LEER
04/03/17
NO CHANGE
Target $141
LEER
Outperform
Incyte price target raised to $141 from $130 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $141 from $130 as he sees epacadostat better positioned in the emerging IO combination landscape. The analyst notes that the company and Bristol-Myers (BMY) have announced that both companies will advance the combination of Opdivo and epacadostat into several registration trials in 2017. He reiterates an Outperform rating on Incyte's shares.
04/03/17
JPMS
04/03/17
NO CHANGE
JPMS
Overweight
Incyte trial news 'another clear positive,' says JPMorgan
JPMorgan analyst Cory Kasimov views the announcement of epacadostat and nivolumab combo moving into Phase 3 studies in first-line non-small cell lung cancer as well as first-line head and neck cancer in 2017 as "another clear positive" for Incyte (INCY). The stock in early trading is up 5% to $140.73. The news expands the breadth of the epacadostat combinations beyond just Merck (MRK) and could ease fears that Bristol-Myers (BMY) is only focused on its internal molecule, Kasimov tells investors in a research note. The analyst continues to be encouraged by Incyte's progress in immuno-oncology and keeps an Overweight rating on the shares.
04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.

TODAY'S FREE FLY STORIES

FCX

Freeport McMoRan

$19.96

0.56 (2.89%)

21:10
01/21/18
01/21
21:10
01/21/18
21:10
Downgrade
Freeport McMoRan rating change  »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

DCM

NTT DoCoMo

$24.74

0.08 (0.32%)

21:09
01/21/18
01/21
21:09
01/21/18
21:09
Downgrade
NTT DoCoMo rating change  »

NTT DoCoMo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$53.01

0.65 (1.24%)

, PETS

PetMed Express

$53.24

2.67 (5.28%)

20:25
01/21/18
01/21
20:25
01/21/18
20:25
Earnings
Notable companies reporting before Monday's open »

Notable companies…

HAL

Halliburton

$53.01

0.65 (1.24%)

PETS

PetMed Express

$53.24

2.67 (5.28%)

OPB

Opus Bank

$28.70

0.05 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

20:00
01/21/18
01/21
20:00
01/21/18
20:00
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

SNE

Sony

$49.89

0.72 (1.46%)

BA

Boeing

$337.73

-2.43 (-0.71%)

WMT

Walmart

$104.59

0.29 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 07

    Feb

  • 20

    Feb

  • 21

    Feb

  • 28

    Feb

  • 18

    Mar

XRX

Xerox

$31.80

0.43 (1.37%)

19:18
01/21/18
01/21
19:18
01/21/18
19:18
Periodicals
Icahn, Deason pushing for Xerox to explored sale, WSJ reports »

Carl Icahn and Darwin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

18:22
01/21/18
01/21
18:22
01/21/18
18:22
Periodicals
Facebook to open three new digital training hubs in Europe, Reuters says »

Facebook said it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 28

    Feb

TWX

Time Warner

$93.36

0.39 (0.42%)

, CMCSA

Comcast

$42.50

0.65 (1.55%)

17:56
01/21/18
01/21
17:56
01/21/18
17:56
Hot Stocks
Box Office Battle: 'Jumanji' wins weekend with $20M »

Once again, Sony's…

TWX

Time Warner

$93.36

0.39 (0.42%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

SNE

Sony

$49.89

0.72 (1.46%)

FOX

21st Century Fox

$36.26

0.53 (1.48%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

LGF.A

Lionsgate

$35.42

0.92 (2.67%)

DIS

Disney

$110.59

0.17 (0.15%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

CTIC

CTI BioPharma

16:11
01/21/18
01/21
16:11
01/21/18
16:11
Conference/Events
CTI BioPharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ZSAN

Zosano Pharma

$0.45

-0.0387 (-7.92%)

16:00
01/21/18
01/21
16:00
01/21/18
16:00
Conference/Events
Zosano Pharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SANM

Sanmina

$35.45

0.5 (1.43%)

15:39
01/21/18
01/21
15:39
01/21/18
15:39
Conference/Events
Sanmina to hold a conference call »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

12:05
01/21/18
01/21
12:05
01/21/18
12:05
Periodicals
Amazon automated grocery store opens Monday, Reuters says »

Amazon will open its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 18

    Mar

TWTR

Twitter

$23.66

-0.38 (-1.58%)

09:07
01/21/18
01/21
09:07
01/21/18
09:07
Periodicals
Twitter COO in discussions to become SoFi CEO, WSJ reports »

Twitter's COO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

CLF

Cleveland-Cliffs

$8.49

0.08 (0.95%)

09:02
01/21/18
01/21
09:02
01/21/18
09:02
Hot Stocks
Cleveland-Cliffs addresses ''inaccurate media reports' on Nashwauk property »

Cleveland-Cliffs said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.